HC Wainwright Has Negative Estimate for BCAX Q1 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a report issued on Monday, April 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.73) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

A number of other equities analysts also recently commented on the company. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a report on Thursday, March 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Stock Down 2.4 %

NASDAQ BCAX opened at $10.15 on Thursday. Bicara Therapeutics has a one year low of $8.91 and a one year high of $28.09. The company has a 50-day simple moving average of $12.79 and a 200-day simple moving average of $16.93.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $582,000. Wellington Management Group LLP acquired a new position in shares of Bicara Therapeutics during the third quarter valued at $19,458,000. Jane Street Group LLC bought a new stake in shares of Bicara Therapeutics during the third quarter valued at about $309,000. Barclays PLC acquired a new stake in Bicara Therapeutics in the third quarter worth about $255,000. Finally, Geode Capital Management LLC acquired a new stake in Bicara Therapeutics in the third quarter worth about $1,239,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.